Keros Therapeutics (NASDAQ:KROS) Now Covered by Oppenheimer

Research analysts at Oppenheimer initiated coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Tuesday, Marketbeat.com reports. The firm set an “outperform” rating and a $102.00 price target on the stock. Oppenheimer’s target price indicates a potential upside of 123.93% from the company’s previous close.

Several other brokerages also recently commented on KROS. Wedbush restated an “outperform” rating and set a $86.00 target price on shares of Keros Therapeutics in a report on Thursday, February 29th. Truist Financial reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $105.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $88.29.

Keros Therapeutics Price Performance

KROS stock opened at $45.55 on Tuesday. The business has a fifty day moving average price of $51.98 and a 200 day moving average price of $54.27. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -8.84 and a beta of 1.24.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.12. The firm had revenue of $0.08 million for the quarter. The firm’s revenue was down 97.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.26) EPS. On average, equities analysts expect that Keros Therapeutics will post -4.98 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KROS. China Universal Asset Management Co. Ltd. raised its position in Keros Therapeutics by 356.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after acquiring an additional 2,702 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares during the period. Arizona State Retirement System purchased a new position in Keros Therapeutics in the fourth quarter valued at approximately $231,000. Bayesian Capital Management LP bought a new position in Keros Therapeutics during the first quarter valued at $267,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after purchasing an additional 2,822 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.